Cisatracurium Fresenius Kabi 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium fresenius kabi 2 mg/ml inj./inf. sol. i.v. amp.

fresenius kabi sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Fresenius Kabi 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium fresenius kabi 2 mg/ml inj./inf. sol. i.v. amp.

fresenius kabi sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Fresenius Kabi 5 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium fresenius kabi 5 mg/ml inj./inf. sol. i.v. amp.

fresenius kabi sa-nv - cisatracurium besilate 6,7 mg/ml - eq. cisatracurium 5 mg/ml - solution for injection/infusion - 5 mg/ml - cisatracurium besilate 6.7 mg/ml - cisatracurium

Cisatracurium Kalceks 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium kalceks 2 mg/ml inj./inf. sol. i.v. amp.

as kalceks a.s. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Kalceks 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium kalceks 2 mg/ml inj./inf. sol. i.v. amp.

as kalceks a.s. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Kalceks 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium kalceks 2 mg/ml inj./inf. sol. i.v. amp.

as kalceks a.s. - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

Cisatracurium Sandoz 2 mg/ml inj./inf. sol. i.v. amp. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cisatracurium sandoz 2 mg/ml inj./inf. sol. i.v. amp.

sandoz sa-nv - cisatracurium besilate 2,68 mg/ml - eq. cisatracurium 2 mg/ml - solution for injection/infusion - 2 mg/ml - cisatracurium besilate 2.68 mg/ml - cisatracurium

CISATRACURIUM BESYLATE injection, solution United States - English - NLM (National Library of Medicine)

cisatracurium besylate injection, solution

meitheal pharmaceuticals inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. - cisatracurium besylate is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate have been reported [see warnings and precautions (5.4)] . - the use of 10 ml cisatracurium besylate multi-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnin